Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

NASDAQ:EGRX opened at $0.64 on Friday. The stock has a market capitalization of $8.31 million, a PE ratio of 0.54 and a beta of 0.51. Eagle Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $14.78. The company has a fifty day moving average of $3.22 and a two-hundred day moving average of $4.14.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several institutional investors have recently bought and sold shares of EGRX. Perceptive Advisors LLC purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth $971,000. Vanguard Group Inc. grew its stake in Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 2,630 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 100,470 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Eagle Pharmaceuticals in the 1st quarter valued at about $83,000. Finally, Fidelis Capital Partners LLC purchased a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $71,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.